Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
Regina M MyersAgne TaraseviciuteSeth M SteinbergAdam J LambleJennifer SheppardBonnie YatesAlexandra Elizabeth KovachBrent L WoodMichael J BorowitzMaryalice Stetler-StevensonConstance M YuanVinodh PillaiToni FoleyPerry ChungLee ChenDaniel W LeeColleen AnnesleyAmanda M DiNofiaStephan A GruppSamuel JohnDeepa BhojwaniPatrick A BrownTheodore W LaetschLia GoreRebecca A GardnerSusan R RheingoldMichael A PulsipherNirali N ShahPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
With the largest series to date in pediatric CD19-CAR, and, to our knowledge, the first to study the impact of sequential CD19 targeting, we demonstrate that blinatumomab nonresponse and high-disease burden were independently associated with worse RFS and EFS, identifying important indicators of long-term outcomes following CD19-CAR.